OCT-1 as a determinant of response to antileukemic treatment

Date

2011

Authors

Engler, J.
Hughes, T.
White, D.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Clinical Pharmacology and Therapeutics, 2011; 89(4):608-611

Statement of Responsibility

JR Engler, TP Hughes and DL White

Conference Name

Abstract

Despite the excellent responses to imatinib therapy observed in patients with chronic phase chronic myeloid leukemia (CP-CML),<sup>1</sup> ∼25% of these patients demonstrate primary resistance or suboptimal response. <sup>2</sup> Inadequate inhibition of the kinase activity of BCR-ABL<sup>3</sup> due to low intracellular concentrations of imatinib achieved in target leukemic cells has been associated with suboptimal response.<sup>4</sup> The organic cation transporter 1 (OCT-1) has been identified as the major active influx pump for imatinib in CML cells,<sup>4,5</sup> and has therefore been investigated as a cause of suboptimal response in patients treated with imatinib. © 2011 ASCPT.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

© 2011 American Society for Clinical Pharmacology and Therapeutics

License

Grant ID

Call number

Persistent link to this record